Clinical Trial Update: TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TAX (docetaxel) with carboplatin or cisplatin as first-line post-surgery therapy for ovarian cancer; study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Sanofi | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED